Sutro Biopharma (STRO) Net Margin (2017 - 2025)

Sutro Biopharma has disclosed Net Margin across 9 years of filings, most recently posting 708.41% for Q4 2025.

• Net Margin for Q4 2025 came in at 708.41%, down 173899.0% year-over-year; the trailing twelve-month figure through Dec 2025 was 210.45% (down 20602.0% YoY), and the FY2025 annual result was 186.45%, down 18258.0% from the prior year.
• Net Margin came in at 708.41% for Q4 2025 at Sutro Biopharma, down from 586.58% in the prior quarter.
• In the past five years, Net Margin ranged from a high of 1030.58% in Q4 2024 to a low of 1146.05% in Q1 2025.
• The 5-year median for Net Margin is 360.34% (2021), against an average of 292.9%.
• Across the five-year window, Net Margin jumped 100326 bps in 2024 and sank 173899 bps in 2025, its largest moves.
• Sutro Biopharma's Net Margin stood at 357.85% in 2021, then retreated by 12 bps to 400.76% in 2022, then soared by 107 bps to 27.32% in 2023, then soared by 3673 bps to 1030.58% in 2024, then tumbled by 169 bps to 708.41% in 2025.
• The last three Net Margin figures came in at 708.41% (Q4 2025), 586.58% (Q3 2025), and 18.04% (Q2 2025), per Business Quant data.